Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.82 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.82 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.82 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.82 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14101236 | 0.94 | MAPK14 (0.73) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4381769 | 0.94 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4382485 | 0.93 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4380029 | 0.92 | MAPK14 (0.84) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6473101 | 0.92 | MAPK14 (0.90) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4379726 | 0.92 | MAPK14 (0.73) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4381570 | 0.91 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29594799 | 0.91 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL6509799 | 0.91 | MAPK14 (0.71) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL2708583 | 0.91 | MAPK14 (0.84) | MAPK14ROCK2MAPK12MAPK11STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| EP-2102161-B1 | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide | PFIZER PROD INC (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2102161-B1 | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide | PFIZER PROD INC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2102161-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | Pfizer Products Incorporated (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885ROCK2 761/4885MAPK12 50/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885ROCK2 983/4885MAPK12 50/4885 |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | CYP4X1, CYP4B1, KDM4B | MAPK14 2841/4885ROCK2 1833/4885MAPK12 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.